1247 results about "Platelet" patented technology

The invention relates to the technical field of target detection, and discloses a blood cell detection method based on improved YOLOv8. According to the method, a convolutional attention module (CBAM) is introduced, so that the detection performance of the model on a shielded small target is improved; a new loss function S-MPDIOU is set, so that the accuracy and robustness of the loss function are further improved; the multi-scale feature fusion technology is adopted to better capture blood cell information of different sizes, so that the model can more accurately identify small target platelets; the recall rate is improved by improving a non-maximum suppression (NMS) algorithm, and particularly under the condition of dense blood cells or complex forms, the improved NMS algorithm can more effectively solve the overlapping problem and reduce false detection and missing detection. Through testing, the model can accurately identify and position different types of blood cells such as red blood cells, white blood cells and blood platelets in an image, and a new effective method is provided for blood cell detection.

An optical detection assembly for monitoring a fluid includes a light source, a light detector array, and a controller. The controller receives signals from the light detector array that are indicative of the intensity of light received by the light detector array after the light has passed through the fluid. The controller generates a scattering profile based on the signals, with the scattering profile including rising and falling edges each having a slope. The controller calculates one or both slopes and determines the platelet mass index (for a platelet-containing fluid) and / or the concentration of a substance in the fluid based on said slope(s). The optical detection assembly may also be used to analyze a reference fluid having a known concentration of the substance, with signals received by the controller when analyzing the reference fluid being a factor when determining the concentration of the substance in the fluid of interest.

The invention provides an improved mesenchymal stem cell culture method and a culture medium used by the improved mesenchymal stem cell culture method, and belongs to the technical field of cell culture. The invention provides an improved mesenchymal stem cell culture medium. Comprising the following exogenous additive components: recombinant human serum albumin, recombinant transferrin, a recombinant human epidermal growth factor, a basic fibroblast growth factor, a platelet-derived growth factor, insulin, L-glutamine, reduced glutathione, beta-mercaptoethanol, sodium selenite, mycillin, allicin, heparin and a proliferation promoting agent. The proliferation promoting agent comprises paeoniflorin, panax notoginseng saponins, lycium barbarum polysaccharide and a snow lotus herb alcohol extract. When the culture medium is used for culturing the mesenchymal stem cells, the cell viability and multiplication capacity of the mesenchymal stem cells can be remarkably improved, the cell viability is improved by 50% or above, the cell multiplication capacity is improved by 40% or above, and the culture medium has great application potential in the aspect of culture of the mesenchymal stem cells.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a targeted liposome as an active component in preparation of a medicine for treating ischemic brain injury. The targeted lipidosome for treating cerebral arterial thrombosis is prepared by fusing the lipidosome and the platelet-neutrophil aggregate membrane, realizes efficient and specific targeting of an ischemic brain region, effectively reduces brain tissue infarction and damage of a new region, relieves brain inflammation through multi-channel regulation and control, and improves the cerebral arterial thrombosis treatment effect. The compound can be used as an active ingredient for preparing a medicine for treating ischemic brain injury. And after the target liposome is further coated with a rutin drug, the synergistic treatment effect is realized. The liposome medicine can be used as an active component and has a good application prospect in treatment of ischemic brain injury diseases.

The invention provides a severe fever with thrombocytopenia syndrome risk prediction model and a construction method and application thereof, first 10 relatively important risk factors are respectively selected through a machine learning algorithm, and coincident risk factors of the two algorithms are Virus, MYO, UREA, AGE, DD and BNP. According to the method, an extreme gradient boosted tree (XGBOOST) is adopted to score a variable set, and when the first five variables are selected, the model score is the highest, so that five prediction indexes Virus, MYO, UREA, AGE and DD are selected to construct an SFTS onset risk prediction model. The model has a good prediction value for SFTS prognosis, or the model can be applied to SFTS prognosis evaluation.

The invention relates to the technical field of nano-drugs, in particular to low-intensity focused ultrasound response nanoparticles for enhancing thrombus targeting and penetration, a preparation method of the nanoparticles and application of the nanoparticles in anti-thrombus treatment. The low-intensity focused ultrasound response nanoparticle for enhancing thrombus targeting and penetration comprises a platelet membrane shell, and a core is formed by wrapping perfluoropentane and L-arginine with polylactic acid-glycolic acid copolymer-polyethylene glycol. The platelet membrane ensures that the nanoparticles specifically target a thrombus part; under the stimulation of LIFU, the nanobubbles penetrate through the deep layer of thrombus, L-arginine is oxidized into L-citrulline, and nitric oxide is formed. Meanwhile, the LIFU triggers liquid-gas phase change and nitric oxide release, the ultrasonic cavitation effect is enhanced through the synergistic effect, thrombus structures including red blood cells, blood platelets and fibrin are specifically attacked, and efficient thrombolysis treatment is achieved. According to the technical scheme, the technical problem that the thrombolysis effect of ultrasonic nanoparticles is not ideal can be solved, and good clinical application prospects are achieved.

The invention discloses a kit and a method for HLA cross reaction group and HPA genotyping. The system for HLA cross reaction group and HPA genotyping detection is obtained through respective combination design of two different primers on the basis of common specific SNP loci, and rapid, simple, low-cost and high-throughput HLA epitope and HPA genotyping detection can be realized, so that platelet infusion ineffectiveness and immune platelet infusion ineffectiveness are more effectively prevented.

A triple droplet type digital PCR (ddPCR) detection method for the severe fever with thrombocytopenia syndrome virus (SFTSV), spotted heat group rickettsia (SFGR) and tsutsugamushi Ot is established. According to the method, specific primers and probes are designed based on an SFTSV L gene, an SFGR 17Kd gene and an Ot 47Kd htrA gene, the reaction temperature and the concentration of the primers and probes are optimized to establish an SFTSV, SFGR and Ot triple ddPCR reaction system, and the specificity, sensitivity and repeatability of the triple ddPCR reaction system are analyzed. According to results, the optimal primer concentration and probe concentration of triple digital PCR are 600nmol / L and 250nmol / L respectively, and the optimal annealing temperature is 60 DEG C; the correlation coefficients of the triple ddPCR SFTSV, the triple ddPCR SFGR and the triple ddPCR Ot standard curve are 0.98, 0.99 and 0.98 respectively, and the lowest detection lower limits are 0.59 copies / mu L, 0.46 copies / mu L and 0.36 copies / mu L respectively. According to the invention, the SFTSV, SFGR and Ot triple digital PCR detection method is established, the sensitivity is high, the specificity is strong, and quantitative detection of three pathogens in SFTS suspected cases can be realized.

The invention discloses a platelet stress state assessment method. The method comprises the following steps: preparing a platelet suspension; incubating the platelet suspension by using an EAAT2 polyclonal primary antibody and a flow fluorescent secondary antibody in combination with a monoclonal antibody of a platelet related marker and / or a monoclonal antibody of Annexin V, and preparing a sample to be detected; detecting a specific signal of the sample through a flow cytometry; and analyzing the specific signal to confirm the stress condition of the sample. According to the method, multi-parameter data of a single platelet can be flexibly processed, and specific clustering analysis of the platelet subgroup is realized in combination with the expression characteristics of the EAAT2 membrane protein. In addition, flexible and efficient statistical analysis can be carried out on inter-group differences of the parameters, correlation between the parameters and the like, and finally personalized accurate diagnosis and analysis of the platelet quality and activation state of the subject are achieved.

The invention relates to bionic ferroptosis nanoparticles loaded with superparamagnetic iron oxide nanoparticles as well as a preparation method and application of the bionic ferroptosis nanoparticles. The biomimetic ferroptosis nano-particles are obtained by loading the superparamagnetic iron oxide nano-particles packaged by the biomimetic platelet membrane, Erastin and lactate oxidase together, and are used for guiding magnetic resonance imaging and inducing tumor cell ferroptosis. According to the method, ferroptosis is induced through Erastin, lactic acid is removed through lactate oxidase, and ferroptosis is enhanced. In addition, lactic acid is oxidized to generate hydrogen peroxide, the hydrogen peroxide is converted into cytotoxic hydroxyl radicals, and cell death is further accelerated. When the PM-ESLNP is combined with an alphaPD-L1 immunotherapy, the PM-ESLNP obviously inhibits tumor growth and metastasis in a liver cancer mouse model, and the result exceeds that of a single immunotherapy. In addition, the superparamagnetic nanoparticles in the PM-coated ESLNP can be used for carrying out real-time MRI (Magnetic Resonance Imaging) monitoring on the treatment effect. According to the invention, a groundbreaking MRI guiding method is introduced, so that ferroptosis of tumors can be enhanced and tumor immunotherapy can be synergistically improved.

A type of additive based on a fluorinated carbamate prepolymer, a preparation method therefor, and a use thereof in the preparation of a medical fluorinated anticoagulant polyurethane material. The preparation method of the additive comprises: reacting a polyester / polyether diol, a diisocyanate and a fluorinated small-molecule diol, to obtain a carbamate prepolymer having an isocyanate end group, and then capping with a monohydric alcohol having a fluorinated carbon chain, to obtain an additive based on a fluorinated carbamate prepolymer. The additive has a high fluorine content. After being blended with a polyurethane masterbatch, fluorine atoms having low surface energy can be enriched on the surface of the material, and the fluorine atom content on the surface of the material can be as high as 60%. This effectively reduces the adhesion of plasma proteins, cells and platelets on the surface of the material, providing the medical polyurethane material with an excellent anticoagulant effect. In addition, it maintains the excellent mechanical properties of polyurethane, and is thus widely applicable in the preparation of medical fluorinated anticoagulant polyurethane materials.

The invention relates to application of a platelet reaction protein 4 in preparation of an alopecia medicine, and belongs to the field of medical biology. The invention aims to solve the technical problems of limited curative effect, obvious side effect and narrow application range of the existing alopecia treatment medicine. The invention provides an application of a platelet reaction protein 4 (THBS4) in preparation of an alopecia medicinal preparation, which can promote hair follicles to be converted from a resting period to a growing period by regulating and controlling a mechanical microenvironment around the hair follicles, enhancing the interaction between fibroblasts and hair follicle stem cells and activating regeneration signal channels in hair papilla and hair bud areas. The traditional Chinese medicine composition breaks through the limitation that existing treatment only aims at specific alopecia types, and can be widely applied to various alopecia diseases such as androgenetic alopecia, pressure alopecia and alopecia after chemotherapy. And compared with the traditional medicine, the traditional Chinese medicine composition has the advantages of quick response, no skin irritation reaction and improved hair follicle regeneration efficiency, and provides a brand new solution for safe and efficient treatment of alopecia.

The present disclosure relates to unimolecular core-shell nanoparticle, nanoclusters thereof, and platelet biomimetic nanoclusters thereof. The disclosed compositions are useful for treating a subject with a disease or condition, such as a cardiovascular disease. In a further aspect, the cardiovascular disease can be a vascular stenosis or restenosis. Also described herein are methods of making and using the unimolecular core-shell nanoparticle, nanoclusters thereof, and platelet biomimetic nanoclusters thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The present invention relates to the field of biomedicine, and specifically is a method for detecting platelet markers of non-small cell lung cancer, comprising the steps of: A. acquiring a gene data source; B. preprocessing gene data; C. analyzing gene differences; D. screening prognostic genes; E. selecting prognostic characteristic genes; and F. displaying analysis results. The present invention can determine characteristic genes that are closely related to the prognosis of patients with non-small cell lung cancer: by analyzing differential genes between different subtypes, the present invention determines ten characteristic genes that are closely related to the prognosis of patients with non-small cell lung cancer, providing new clues for further prognosis evaluation.

Provided herein are compositions comprising allogeneic human plasma and platelet derived product, and methods for making the compositions and using the compositions as a therapeutic for example, in orthopedic indications.

The invention provides a chimeric bivalent SFTSV (severe fever with thrombocytopenia syndrome virus) mRNA (messenger ribonucleic acid) vaccine, which is characterized in that the vaccine co-expresses an SFTSV envelope protein precursor GPC and a nucleoprotein NP in series through a flexible joint. Through humoral immunity, cellular immunity and challenge protection effect evaluation, the effectiveness of the mRNA vaccine provided by the invention is verified. Research results show that the prepared SFTSV mRNA vaccine can generate a good immune protection effect by only needing one mRNA, has the characteristics of simple industrial production, easy quality control and the like, and is an ideal choice of the SFTSV vaccine.

The invention provides a diagnostic marker for systemic lupus erythematosus and application of the diagnostic marker, and belongs to the technical field of biological medicine. The diagnostic marker is at least one protein of PDGFA (Platelet Derivative Growth Factor Amplification), APOD (Adenosine Polymerase Chain Reaction), CFHR5, AMDHD1 and SCGB3A1; the amino acid sequence of the PDGFA is as shown in SED ID NO. 1; the amino acid sequence of the APOD is as shown in SED ID NO. 2; the amino acid sequence of the CFHR5 is as shown in SED ID NO.3; the amino acid sequence of AMDHD1 is as shown in SED ID NO. 4; and the amino acid sequence of the SCGB3A1 is as shown in SED ID (Sequence of Identification) NO.5. According to the present invention, the five proteins are adopted as the SLE disease diagnosis biomarker independently or in the combination manner, such that advantages of high accuracy, high sensitivity and high specificity are provided, and the new target spot is provided for the diagnosis, the intervention improvement and the like of the SLE patient.

The invention discloses a wound-targeted intelligent nano-drug as well as a preparation method and application thereof. The wound-targeted intelligent nano-drug comprises a platelet membrane and drug-loaded nano-particles, wherein the platelet membrane coats the drug-loaded nano-particles; the drug-loaded nanoparticles contain a tumor angiogenesis inhibitor; the surface of the platelet membrane is connected with an anti-PDL1 antibody. The wound-targeted intelligent nano-drug can significantly improve the curative effect of a tumor angiogenesis inhibitor (sorafenib) and anti-PDL1 combined use, improve the biological distribution of the drug, reduce the toxic and side effects caused by the combined use of the sorafenib and anti-PDL1, greatly reduce the postoperative recurrence rate of early liver cancer, has a strong postoperative recurrence inhibition capability, and has a good application prospect. The biological safety is relatively excellent.

The utility model discloses a platelet shaking device for blood transfusion, which relates to the technical field of shaking devices and comprises a shaking box and a box cover. The device comprises a shaking box, a box cover is arranged on the upper side of the shaking box, a placement assembly is arranged in the middle of the interior of the shaking box and comprises an objective table, an electronic scale and a heat preservation plate, the objective table is arranged in the middle of the interior of the shaking box, a cavity is formed in the objective table, the electronic scale is fixedly arranged at the bottommost part of the cavity, and the heat preservation plate is fixedly arranged on the upper side of the electronic scale. A shaking mechanism is arranged on the surface of the rear side of the objective table, and a driving mechanism is arranged on the rear side of the shaking mechanism, so that the blood transfusion bag can be shaken, the cell viability of platelets in blood is further improved, the platelets in the blood are prevented from being accumulated together, and then the body of a patient is prevented from absorbing the platelets in the conveyed blood; the stability of the device can be guaranteed, blood transfusion efficiency can be improved, and practicability is high.

The invention belongs to the technical field of medical equipment, and particularly relates to a blood growth factor extraction device and an information loading system.The blood growth factor extraction device comprises a box body used for connecting all components; the blood centrifugal assembly is arranged in the box body, and the blood centrifugal assembly is used for centrifugally removing red blood cells of the blood; the information field assembly is arranged in the box body, the information field assembly is connected with the blood centrifugal assembly, and the information field assembly is used for performing scalar wave action on blood in the blood centrifugal assembly and loading specific life factor information into plasma; the disinfection assembly is arranged in the box body, the disinfection assembly is connected with the blood centrifugal assembly, the disinfection assembly is used for disinfecting test tubes in the blood centrifugal assembly, and it is guaranteed that wound repair factors, blood platelets, growth factors and the like are more easily and sufficiently separated during separation and preparation.

The invention provides a platelet membrane bionic nano-drug delivery system as well as a preparation method and application thereof, and relates to the technical field of medicines. According to the invention, through membrane engineering modification, a wrapping material obtained through hybridization of a platelet membrane and an NK cell exosome is used for loading ginsenoside Rg3 for the first time, a ginsenoside Rg3 delivery system with high encapsulation efficiency and high drug loading capacity is obtained, and the system has excellent stability and can be stored for a long time in normal-temperature and high-temperature environments; the ginsenoside Rg3-loaded platelet membrane bionic nano-drug delivery system is simple in preparation method and suitable for wide popularization and application; according to the ginsenoside Rg3-loaded platelet membrane bionic nano-drug delivery system, the lung cancer treatment effect of ginsenoside Rg3 can be effectively improved, a novel drug is provided for lung cancer treatment, and the drug is high in safety, high in biocompatibility, free of adverse reaction in the treatment process and obvious in anti-inflammatory effect.

The invention relates to the technical field of hemostatic materials, in particular to a clay mineral-based aerogel hemostatic material and a preparation method thereof. The invention discloses a preparation method of a clay mineral-based aerogel hemostatic material. The preparation method comprises the following steps: S1, uniformly dispersing clay minerals and sodium alginate in deionized water respectively, and stirring to prepare slurry and sol for later use; s2, uniformly mixing the slurry and the sol, preparing a mixed sol, introducing the mixed sol into a mold, dropwise adding a proper amount of a metal salt solution, and standing to obtain a standing product; s3, freeze-drying the standing product to obtain the clay mineral-based aerogel hemostatic material. The composite material disclosed by the invention combines the adsorbability of clay and the biocompatibility of sodium alginate, has excellent biocompatibility and high safety, and shows excellent performance in the aspects of absorbing and concentrating tissue fluid, and the composite aerogel can quickly activate platelets and stimulate blood coagulation factors to efficiently coagulate blood, and has efficient hemostasis capability.

The present invention relates to the technical field of diabetes, and in particular to a controlled-release diabetic wound healing promoting treatment method, comprising the following treatment experimental steps: step S1: preparation of Hst1@PNPs; step S2: Coomassie brilliant blue staining; step S3: scanning and transmission electron microscopy detection; in the present invention, a slow-release Hst1 treatment method is constructed by encapsulating Hst1 into platelet membrane vesicles derived from autologous blood. On the one hand, the PNPs encapsulate the linear Hst1 peptide structure to prevent it from being rapidly degraded by high proteases in diabetic wound exudate, thereby improving bioavailability. On the other hand, the PNPs can adsorb excess LPS in the wound exudate, and cooperate with Hst1 to achieve anti-inflammatory and anti-oxidative stress effects. Subsequent cell and animal experiments further confirmed that Hst1@PNPs have the effects of anti-inflammatory, scavenging ROS, promoting re-epithelialization, collagen deposition and angiogenesis, thereby promoting diabetic wound healing.

The invention provides a method for generating platelet-like particles based on MEG-01 cells and evaluating functions of the platelet-like particles, and belongs to the technical field of cell biology. The invention provides a method for generating PLPs by inducing MEG-01 cells. According to the method, the MEG-01 cells are differentiated into PLPs with platelet characteristics by utilizing a PMA inducer. The PLPs disclosed by the invention has characteristic surface marker expression consistent with that of natural platelets, can respond to stimulation of an activator ADP, and shows biological functional characteristics of the platelets. The method for generating PLPs is simple and economical, experimental conditions are highly controllable, and an economical, efficient and repeatable in-vitro model is provided for functional research related to platelets.

Platelet-derived extracellular vesicles (PEVs) containing mitochondria are used in treating ocular disorders or symptoms of ocular disorders. The PEVs are collected by obtaining blood from one or more donors, adding an anticoagulant and a buffer to the blood to form a mixture, separating the mixture into a supernatant and platelet-rich plasma (PRP), collecting the PRP, stimulating the collected PRP to displace the extracellular vesicles from the platelets in the PRP, and collecting the extracellular vesicles as PEVs.

The invention is applicable to the technical field of biological materials, and provides a preparation method of photocuring autoplatelet concentrate hydrogel, which comprises the following steps: preparing methacrylated gelatin; preparing injectable platelet-rich fibrin; the preparation method comprises the following steps: preparing methacrylated iPRF hydrogel: weighing 500mg of a GelMA hydrogel precursor, placing the GelMA hydrogel precursor in 4ml of PBS, placing the PBS in a water bath box at 55 DEG C, and fully dissolving the GelMA hydrogel precursor to obtain a GelMA solution with the mass fraction of 10%; weighing 1mg of LAP photoinitiator, adding the LAP photoinitiator into the system solution, and stirring for 5 minutes; loading the liquid into a centrifugal tube, then adding 1ml of iPRF, fully and uniformly mixing the two components by using an injector, and irradiating for 30s under ultraviolet light of 405nm to crosslink the two components to obtain the iPRF-MA hydrogel. The method is mild in reaction condition and can be used at room temperature; the method is simple in experiment, good in repeatability and suitable for batch production. Meanwhile, the autoblood of the patient is taken as a raw material and is easy to obtain, low in cost and free of side effects, and real personalized medical treatment is realized.

The monoclonal antibody of the glycoprotein Gn of the severe fever with thrombocytopenia syndrome virus is screened on the basis of immune repertoire sequencing, and the biological characteristics of the monoclonal antibody are identified. The method comprises the following steps: taking purified SFTSV-Gn as bait, taking virus specific B cells from an immunized female BALB / c mouse B cell bank, selecting an antibody sequence with potential binding activity by utilizing a 10 * immune repertoire sequencing method in combination with bioinformatics analysis, constructing the antibody sequence to an eukaryotic expression vector pcDNA3.4, expressing and purifying a monoclonal antibody, and identifying the biological activity of the monoclonal antibody. 14 antibodies are selected from 3544 captured B cells, functional verification shows that 12 antibodies can be combined with SFTSV-Gn glycoprotein, and the Gn-5 antibody and the Gn-7 antibody have high combining capacity; western blot, indirect immunofluorescence test and flow cytometry prove that the antibody can specifically recognize the SFTSV, the effective concentration is as low as 2 mu g / mL, and a foundation is laid for development of a rapid diagnosis reagent for the SFTSV.

The present invention provides a use of a purified platelet-derived exosome dry powder for relieving inflammation or injury, wherein the number of platelet-derived exosomes in each gram of the purified platelet-derived exosome dry powder is more than or equal to 1×1010.

Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCCcorrected, alanine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.

The invention discloses a traditional Chinese medicine composition with an effect of improving artery blood vessel plaque and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The technical problem to be solved is to provide a traditional Chinese medicine composition capable of improving vascular plaques such as carotid artery, aortic arch, brachial trunk, subclavian artery and the like aiming at the current situation that adverse reactions exist when statin lipid-lowering drugs and antiplatelet drugs are taken for a long time to treat artery vascular plaques. According to the technical scheme, the traditional Chinese medicine composition with the effect of improving the artery blood vessel plaque is characterized by comprising radix puerariae, red yeast rice, folium cortex eucommiae, hippophae rhamnoides leaves and natto.